AdipoR1–AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis

Bissell MJ, Weaver VM, Lelievre SA, Wang F, Petersen OW, Schmeichel KL. Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res. 1999;59:1757–63s. discussion 1763s–64s.

Google Scholar 

Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.

Google Scholar 

Ringel AE, Drijvers JM, Baker GJ, Catozzi A, Garcia-Canaveras JC, Gassaway BM, et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell. 2020;183:1848–66.

Google Scholar 

Achyut BR, Yang L. Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology. 2011;141:1167–78.

Google Scholar 

Parker TM, Gupta K, Palma AM, Yekelchyk M, Fisher PB, Grossman SR, et al. Cell competition in intratumoral and tumor microenvironment interactions. EMBO J. 2021;40:e107271.

Google Scholar 

Shiau C, Cao J, Gong D, Gregory MT, Caldwell NJ, Yin X, et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat Genet. 2024;56:2466–78.

Google Scholar 

Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–5.

Google Scholar 

Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94:715–25.

Google Scholar 

Bailis W, Shyer JA, Chiorazzi M, Flavell RA. No oxygen? No glucose? No problem: fatty acid catabolism enhances effector CD8(+) TILs. Cancer Cell. 2017;32:280–1.

Google Scholar 

Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, et al. Simultaneous targeting of TGF-beta/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell. 2021;39:1388–403.e1310.

Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.

Google Scholar 

Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol. 2020;21:95–104.

Google Scholar 

Sezer A, Kilickap S, Gumus M, Bondarenko I, Ozguroglu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592–604.

Google Scholar 

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:643–54.

Google Scholar 

Mukherjee A, Bilecz AJ, Lengyel E. The adipocyte microenvironment and cancer. Cancer Metastasis Rev. 2022;41:575–87.

Google Scholar 

Pestel J, Blangero F, Watson J, Pirola L, Eljaafari A. Adipokines in obesity and metabolic-related-diseases. Biochimie. 2023;212:48–59.

Google Scholar 

Sato S. Adipo-oncology: adipocyte-derived factors govern engraftment, survival, and progression of metastatic cancers. Cell Commun Signal. 2024;22:52.

Google Scholar 

Tilg H, Ianiro G, Gasbarrini A, Adolph TE. Adipokines: masterminds of metabolic inflammation. Nat Rev Immunol. 2025;25:250–65.

Google Scholar 

Dogra S, Neelakantan D, Patel MM, Griesel B, Olson A, Woo S. Adipokine Apelin/APJ pathway promotes peritoneal dissemination of ovarian cancer cells by regulating lipid metabolism. Mol Cancer Res. 2021;19:1534–45.

Google Scholar 

Huang CL, Achudhan D, Liu PI, Lin YY, Liu SC, Guo JH, et al. Visfatin upregulates VEGF-C expression and lymphangiogenesis in esophageal cancer by activating MEK1/2-ERK and NF-kappaB signaling. Aging. 2023;15:4774–93.

Google Scholar 

Mallardo M, Scalia G, Raia M, Daniele A, Nigro E. The effects of adiponectin on the behavior of B-cell leukemia cells: insights from an in vitro study. Biomedicines. 2023;11:2585.

Google Scholar 

Li C, Zhang J, Dionigi G, Liang N, Guan H, Sun H. Adiponectin inhibits the progression of obesity-associated papillary thyroid carcinoma through autophagy. Endocrinology. 2024;165:bqae030.

Google Scholar 

Yoshida J, Hayashi T, Munetsuna E, Khaledian B, Sueishi F, Mizuno M, et al. Adipsin-dependent adipocyte maturation induces cancer cell invasion in breast cancer. Sci Rep. 2024;14:18494.

Google Scholar 

Musa Sultan M, Hussein Abdullah T, Abbas Abdullah M, Al-Darkazali W, Sattar Harbi N. Evaluate the serum of irisin, omentin-1, and oxidative status in males with prostatic cancer. Rep Biochem Mol Biol. 2024;13:23–30.

Google Scholar 

Suzuki A, Sato S, Nakaigawa N, Kishida T, Miyagi Y. Combination of blood adiponectin and leptin levels is a predictor of biochemical recurrence in prostate cancer invading the surrounding adipose tissue. Int J Mol Sci. 2024;25:8970.

Google Scholar 

Nagasaka H, Sato S, Suzuki A, Terao H, Nakamura Y, Yoshihara M, et al. Clinicopathological significance of extranodal adipose tissue invasion in metastatic lymph nodes in patients with prostate cancer. Prostate. 2025;85:283–93.

Google Scholar 

Rivera-Suarez BA, Garcia Gonzalez VG, Chimal-Vega B, Navarro Padron AC, Galindo-Hernandez O, Vique-Sanchez JL. Potential ligands to resistin against prostate cancer, evaluated by molecular docking and in vitro assays to develop an anticancer drug. Chem Biodivers. 2025;22:e202500189.

Google Scholar 

Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab. 2004;15:362–9.

Google Scholar 

Beck D, de Lange AG, Alnaes D, Maximov II, Pedersen ML, Leinhard OD, et al. Adipose tissue distribution from body MRI is associated with cross-sectional and longitudinal brain age in adults. Neuroimage Clin. 2022;33:102949.

Google Scholar 

Okudzhava L, Schulz S, Fischi-Gomez E, Girard G, Machann J, Koch PJ, et al. White adipose tissue distribution and amount are associated with increased white matter connectivity. Hum Brain Mapp. 2024;45:e26654.

Google Scholar 

Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer. 2009;16:1197–210.

Google Scholar 

Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010;24:1441–52.

Google Scholar 

Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS. Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther. 2011;10:2234–43.

Google Scholar 

Wang J, Cheng Y, Yin X, Wu J, Luo Y, Wu J, et al. Globular adiponectin inhibits leptin-stimulated esophageal adenocarcinoma cell proliferation via adiponectin receptor 2-mediated suppression of UHRF1. Mol Cell Biochem. 2017;431:103–12.

Google Scholar 

Yang S, Sun Y, Guo Y, Zhao Z, Hu F, Cong L. The glycolysis-related AMPK/ULK signaling pathway mediates the inhibitory effect of adiponectin in prostate cancer cells. Mol Cell Endocrinol. 2024;593:112338.

Google Scholar 

Li C, Zhang J, Dionigi G, Liang N, Guan H, Sun H. Uncovering the connection between obesity and thyroid cancer: the therapeutic potential of adiponectin receptor agonist in the AdipoR2-ULK axis. Cell Death Dis. 2024;15:708.

Google Scholar 

Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013;503:493–9.

Google Scholar 

Akimoto M, Maruyama R, Kawabata Y, Tajima Y, Takenaga K. Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis. Cell Death Dis. 2018;9:804.

Google Scholar 

Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, et al. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019;461:37–46.

Google Scholar 

Takenaga K, Akimoto M, Koshikawa N, Nagase H. Obesity reduces the anticancer effect of AdipoRon against orthotopic pancreatic cancer in diet-induced obese mice. Sci Rep. 2021;11:2923.

Google Scholar 

Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010;464:1313–9.

Google Scholar 

Kadowaki T, Yamauchi T. Adiponectin receptor signaling: a new layer to the current model. Cell Metab. 2011;13:123–4.

Google Scholar 

Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011;13:401–12.

Google Scholar 

Pagano AF, Py G, Bernardi H, Candau RB, Sanchez AM. Autophagy and protein turnover signaling in slow-twitch muscle during exercise. Med Sci Sports Exerc. 2014;46:1314–25.

Google Scholar 

Manley SJ, Olou AA, Jack JL, Ruckert MT, Walsh RM, Eades AE, et al. Synthetic adiponectin-receptor agonist, AdipoRon, induces glycolytic dependence in pancreatic cancer cells. Cell Death Dis. 2022;13:114.

Google Scholar 

Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ. BRCA1/2 serves as a biomarker for poor prognosis in breast carcinoma. Int J Mol Sci. 2022;23:3754.

Google Scholar 

Kim SH, Park WS, Yun SI, Joo J, Joung JY, Seo HK, et al. Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy. Histopathology. 2016;68:673–9.

Google Scholar 

De Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016;21:1181–8.

Google Scholar 

Vidula N, Yau C, Rugo H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat. 2022;194:569–75.

Google Scholar 

Li N, Xu J, Yan X, Liu Q, Zhang M. TROP2 promotes the proliferation of triple-negative breast cancer cells via calcium ion-dependent ER stress signaling pathway. Cell Biochem Biophys. 2024;82:2205–16.

Google Scholar 

Sapio L, Nigro E, Ragone A, Salzillo A, Illiano M, Spina A, et al. AdipoRon affects cell cycle progression and inhibits proliferation in human osteosarcoma cells. J Oncol. 2020;2020:7262479.

Google Scholar 

Keung MY, Wu Y, Badar F, Vadgama JV. Response of breast cancer cells to PARP inhibitors is independent of BRCA status. J Clin Med. 2020;9:940.

Google Scholar 

Alshabi AM, Vastrad B, Shaikh IA, Vastrad C. Exploring the molecular mechanism of the drug-treated breast cancer based on gene expression microarray. Biomolecules. 2019;9:282

Google Scholar 

Yu X, Luo Y, Zhou Y, Zhang Q, Wang J, Wei N, et al. BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. Int J Oncol. 2008;33:555–63.

Google Scholar 

Liu X, Liu H, Zeng L, Lv Y. BRCA1 overexpression attenuates breast cancer cell growth and migration by regulating the pyruvate kinase M2-mediated Warburg effect via the PI3K/AKT signaling pathway. PeerJ. 2022;10:e14052.

Google Scholar 

Yu X, Deng J, Zhang H, Tong J, Wan C, Liu Y, et al. Effects of BRCA1 overexpression via the NRF2 / HO1 / NQO1 pathway on oral cancer cells proliferation, migration, and apoptosis. Heliyon. 2024;10:e38977.

Google Scholar 

Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408:429–32.

Google Scholar 

Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, et al. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res. 2008;68:257–65.

Google Scholar 

Nicholson RI, Johnston SR. Endocrine therapy-current benefits and limitations. Breast Cancer Res Treat. 2005;93:S3–10.

Google Scholar 

Haricharan S, Lei J, Ellis M. Mammary ductal environment is necessary for faithful maintenance of estrogen signaling in ER(+) breast cancer. Cancer Cell. 2016;29:249–50.

Google Scholar 

Izci H, Punie K, Waumans L, Laenen A, Wildiers H, Verdoodt F, et al. Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer. Sci Rep. 2022;12:22498.

Google Scholar 

Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. Eur J Pharm Sci. 2015;76:203–12.

Google Scholar 

Wong CC, Cheng KW, Rigas B. Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther. 2012;341:572–8.

Google Scholar 

Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel. Cancer Res. 2000;60:4146–51.

Google Scholar 

Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318–30.

Google Scholar 

Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117:1068–77.

Google Scholar 

Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010;116:3039–48.

Google Scholar 

Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 2003;278:9073–85.

Google Scholar 

Kaser S, Tatarczyk T, Stadlmayr A, Ciardi C, Ress C, Tschoner A, et al. Effect of obesity and insulin sensitivity on adiponectin isoform distribution. Eur J Clin Invest. 2008;38:827–34.

Google Scholar 

Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.

Google Scholar 

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.

Google Scholar 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.

Google Scholar 

de Bruijn I, Kundra R, Mastrogiacomo B, Tran TN, Sikina L, Mazor T, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023;83:3861–7.

Google Scholar 

Gyorffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024;5:100625.

Google Scholar